 | Up a level |
Journal Article
Dietlein, F., Kalb, B., Jokic, M., Torgovnick, A., Schmitt, A., Buettner, R., Thomas, R. and Reinhardt, H. C. (2015). Combined Chk1-and MK2-inhibition displays robust synergy in KRAS-mutant cancer. Oncol. Res. Treat., 38. S. 169 - 170. BASEL: KARGER. ISSN 2296-5262
Dietlein, F., Thelen, L. and Reinhardt, H. C. (2014). A functional cancer genomics screen reveals an actionable synthetic lethal interaction between the MMR gene MSH3 and the NHEJ gene PRKDC. Oncol. Res. Treat., 37. S. 298 - 300. BASEL: KARGER. ISSN 2296-5262
Golfmann, K., Meder, L., Tharun, L., Dietlein, F., Malcher, F., Koker, M., Buettner, R. and Ullrich, R. T. (2017). Targeting FGFR1 and VEGFR1 displays synergistic treatment effects in FGFR1 overexpressed breast cancer. Oncol. Res. Treat., 40. S. 87 - 88. BASEL: KARGER. ISSN 2296-5262
Hohberg, M., Dietlein, M., Kobe, C., Dietlein, F., Zlatopolskiy, B., Krapf, P., Wild, M., Taeger, P., Neumaier, B. and Drzezga, A. (2018). Biodistribution and radiation dosimetry of the novel F-18-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 45. S. S149 - 2. NEW YORK: SPRINGER. ISSN 1619-7089
Hohberg, M., Kobe, C., Taeger, P., Hammes, J., Schmidt, M., Dietlein, F., Wild, M., Heidenreich, A., Drzezga, A. and Dietlein, M. (2019). Combined Early and Late [Ga-68]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol. Imaging. Biol., 21 (3). S. 558 - 567. NEW YORK: SPRINGER. ISSN 1860-2002
Meder, L., Koenig, K., Dietlein, F., Florin, A., Koker, M., Buettner, R., Heukamp, L. and Ullrich, R. (2018). LIN28B enhanced tumorigenesis in an autochthonous KRASG12V driven lung carcinoma mouse model. Oncol. Res. Treat., 41. S. 291 - 292. BASEL: KARGER. ISSN 2296-5262
Meder, L., Schuldt, P., Thelen, M., Dietlein, F., von Baildon, Bergwelt M., Reinhardt, C. and Ullrich, R. T. (2017). Dual inhibition of anti-VEGF and anti-PD-L1 displays synergistic treatment effects in a small cell lung carcinoma mouse model. Oncol. Res. Treat., 40. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Nogova, L., Papachristou, I., Persigehl, T., Dietlein, F., Zander, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 131 - 132. BASEL: KARGER. ISSN 2296-5262